|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.38 USD | +1.13% |
|
+5.83% | +3.65% |
| 06-04 | Incyte, Mirum Pharmaceuticals to Present New Zilurgisertib Study Results at Conference | MT |
| 06-01 | Wall Street Starts June on Edge |  |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 24 | |||||||
| 28 | |||||||
| 19 | |||||||
| 24 | |||||||
| 16 | |||||||
| 29 | |||||||
| 20 | |||||||
| 26 | |||||||
| 12 | |||||||
| 23 | |||||||
| 21 | |||||||
| 5 | |||||||
| 26 | |||||||
| 9 | |||||||
| 12 | |||||||
| - | 1 | ||||||
| - | 1 | ||||||
| - | - | ||||||
| 10 | |||||||
| Average | 17 | |||||||
| Weighted average by Cap. | 21 |
- Stock Market
- Equities
- INCY Stock
- Sector Incyte Corporation
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition